earnings
NR
NASDAQ · NRIX
Nurix Therapeutics, Inc.
Healthcare · Biotechnology
$25.67
Down-$1.38 (-5.38%)
Updated Sep 23, 2026, 4:45 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.47B
- P/E ratio
- -6.56
- Dividend yield
- 0.00%
- 52-week range
- $8.20 – $28.23
- Volume
- 1.51M
- Avg. volume
- 1.68M
Price performance
NRIX price history
1M range · 20 trading sessions · Daily adjusted prices
NRIX closed at $25.67 after 20 trading sessions, down 4.75% for the selected period.
- Last close
- $25.67
- Period change
- -4.75%
- Period low
- $24.83
- Period high
- $26.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $25.32 | $25.96 | $25.23 | $25.67 | 1.51M |
| Sep 21, 2026 | $25.73 | $25.925 | $25.06 | $25.41 | 1.52M |
| Sep 18, 2026 | $25.32 | $25.795 | $25.01 | $25.44 | 2.84M |
| Sep 17, 2026 | $25.79 | $26.35 | $25.37 | $25.50 | 1.51M |
| Sep 16, 2026 | $24.87 | $25.29 | $24.68 | $25.15 | 1.24M |
| Sep 15, 2026 | $25.47 | $25.495 | $24.27 | $24.83 | 1.25M |
| Sep 14, 2026 | $25.01 | $26.14 | $24.945 | $25.52 | 1.33M |
| Sep 11, 2026 | $26.31 | $26.65 | $25.00 | $25.10 | 1.32M |
| Sep 10, 2026 | $25.89 | $25.99 | $25.50 | $25.81 | 1.03M |
| Sep 9, 2026 | $26.46 | $26.695 | $25.91 | $26.26 | 1.03M |
| Sep 8, 2026 | $25.42 | $26.42 | $25.36 | $26.13 | 1.29M |
| Sep 4, 2026 | $25.19 | $26.22 | $24.97 | $26.14 | 1.23M |
| Sep 3, 2026 | $25.82 | $26.16 | $24.95 | $25.32 | 1.38M |
| Sep 2, 2026 | $26.35 | $26.915 | $25.39 | $25.82 | 1.74M |
| Sep 1, 2026 | $25.47 | $26.11 | $25.47 | $26.04 | 1.6M |
| Aug 31, 2026 | $26.00 | $26.23 | $25.17 | $25.78 | 1.24M |
| Aug 28, 2026 | $26.52 | $26.87 | $26.125 | $26.21 | 929.23K |
| Aug 27, 2026 | $26.795 | $27.50 | $26.235 | $26.875 | 1.26M |
| Aug 26, 2026 | $26.77 | $27.23 | $26.44 | $26.71 | 551.88K |
| Aug 25, 2026 | $26.72 | $27.38 | $26.378 | $26.95 | 1.18M |
Latest NRIX news
The latest Smart Investors Daily articles mentioning NRIX.
Stock researchResearch & News · Analysis
Loading stock research…